Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.

Cancer Res. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.

2.

CCR5 antagonist blocks metastasis of basal breast cancer cells.

Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG.

Cancer Res. 2012 Aug 1;72(15):3839-50. doi: 10.1158/0008-5472.CAN-11-3917. Epub 2012 May 25.

3.

The potential to target CCL5/CCR5 in breast cancer.

Velasco-Velázquez M, Xolalpa W, Pestell RG.

Expert Opin Ther Targets. 2014 Nov;18(11):1265-75. doi: 10.1517/14728222.2014.949238. Epub 2014 Sep 26. Review.

PMID:
25256399
4.

An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.

Norton KA, Wallace T, Pandey NB, Popel AS.

BMC Syst Biol. 2017 Jul 11;11(1):68. doi: 10.1186/s12918-017-0445-x.

5.

Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.

Mohapatra P, Satapathy SR, Das D, Siddharth S, Choudhuri T, Kundu CN.

Toxicol Appl Pharmacol. 2014 Mar 15;275(3):221-31. doi: 10.1016/j.taap.2014.01.011. Epub 2014 Jan 24.

PMID:
24467951
6.

Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.

Sax MJ, Gasch C, Athota VR, Freeman R, Rasighaemi P, Westcott DE, Day CJ, Nikolic I, Elsworth B, Wei M, Rogers K, Swarbrick A, Mittal V, Pouliot N, Mellick AS.

Oncotarget. 2016 Dec 20;7(51):85437-85449. doi: 10.18632/oncotarget.13387.

7.

CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.

Pervaiz A, Zepp M, Mahmood S, Ali DM, Berger MR, Adwan H.

Cell Oncol (Dordr). 2019 Feb;42(1):93-106. doi: 10.1007/s13402-018-0415-3. Epub 2018 Nov 19.

PMID:
30456574
8.

Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo.

Lombardo Y, Filipović A, Molyneux G, Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yagüe E, Michel L, Coombes RC.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16558-63. doi: 10.1073/pnas.1206268109. Epub 2012 Sep 24.

9.

COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.

Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, Postovit LM, Hess D, Lala PK.

Stem Cells. 2016 Sep;34(9):2290-305. doi: 10.1002/stem.2426. Epub 2016 Jun 27.

10.

Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion.

Iliopoulos D, Hirsch HA, Wang G, Struhl K.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402. doi: 10.1073/pnas.1018898108. Epub 2011 Jan 10.

11.

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

Smit L, Berns K, Spence K, Ryder WD, Zeps N, Madiredjo M, Beijersbergen R, Bernards R, Clarke RB.

Oncotarget. 2016 Jan 19;7(3):2596-610. doi: 10.18632/oncotarget.6354.

12.

Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy.

Pervin S, Hewison M, Braga M, Tran L, Chun R, Karam A, Chaudhuri G, Norris K, Singh R.

PLoS One. 2013;8(1):e53287. doi: 10.1371/journal.pone.0053287. Epub 2013 Jan 14. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/5326d117-3f31-4e43-a5c4-9e1fb41719e9.

13.

The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer.

Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, Hejmadi RK, Bicknell R, Eksteen B, Ismail T, Rot A, Adams DH.

Br J Cancer. 2015 Jan 20;112(2):319-28. doi: 10.1038/bjc.2014.572. Epub 2014 Nov 18.

14.

c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.

Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.

Oncogene. 2013 May 30;32(22):2767-81. doi: 10.1038/onc.2012.290. Epub 2012 Jul 16.

PMID:
22797058
15.

Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.

Zhu C, Cheng KW, Ouyang N, Huang L, Sun Y, Constantinides P, Rigas B.

Stem Cells. 2012 Oct;30(10):2065-75. doi: 10.1002/stem.1139.

16.

Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm.

Laudati E, Currò D, Navarra P, Lisi L.

Neurochem Int. 2017 Sep;108:100-108. doi: 10.1016/j.neuint.2017.03.002. Epub 2017 Mar 6.

PMID:
28279751
17.

CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.

18.

Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents.

Arnatt CK, Adams JL, Zhang Z, Haney KM, Li G, Zhang Y.

Bioorg Med Chem Lett. 2014 May 15;24(10):2319-23. doi: 10.1016/j.bmcl.2014.03.073. Epub 2014 Apr 3.

PMID:
24731275
19.
20.

Supplemental Content

Support Center